Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Tanshinone IIA Sulfonate in STEMI
NCT02524964Phase 4Unknown
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of sodium tanshinone IIA sulfonate in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Left Ventricular End-Diastolic Volume Index at 6 months. Status: unknown.
02
Drugs
sodium tanshinone IIA sulfonate
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT02524964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02524964.